Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study

  • Authors:
    • Maki Hagihara
    • Noriyoshi Iriyama
    • Chikashi Yoshida
    • Hisashi Wakita
    • Shigeru Chiba
    • Shinichiro Okamoto
    • Kimihiro Kawakami
    • Naoki Takezako
    • Takashi Kumagai
    • Koiti Inokuchi
    • Kazuma Ohyashiki
    • Jun Taguchi
    • Shingo Yano
    • Tadahiko Igarashi
    • Yasuji Kouzai
    • Satoshi Morita
    • Junichi Sakamoto
    • Hisashi Sakamaki
  • View Affiliations

  • Published online on: September 20, 2016     https://doi.org/10.3892/or.2016.5110
  • Pages: 2976-2982
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite the efficacy and safety of dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP), adverse effects such as pleural effusion (PE) are still a serious concern. We determined the clinical significance of PE incidence using patient data derived from the D-First clinical study. In the present study, chest radiography and quantification of specific lymphocyte subsets were performed routinely after initiation of dasatinib treatment. Among 52 patients with newly diagnosed CML-CP, 17 (33%) developed PE within 18 months after initial dasatinib administration, but all cases were moderate (Grade 1, 10 patients; Grade 2, 7 patients). CD56+ lymphocyte counts at 1 month correlated significantly with the incidence of PE, whereas lymphocytosis did not. The major molecular response (MMR) rate at 3 months (although not at later times) was significantly higher in PE-positive patients than PE-negative patients (59% versus 24%, respectively; P=0.013). Deep molecular response rates did not differ significantly between the PE groups at any time point during the observation period. Our results suggest that an immune-mediated mechanism involving natural killer cells underlies the development of PE in patients receiving dasatinib for 18 months. This mechanism likely promotes transient tumor regression in patients newly diagnosed with CML-CP.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 36 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Inokuchi K, et al: Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncol Rep 36: 2976-2982, 2016
APA
Hagihara, M., Iriyama, N., Yoshida, C., Wakita, H., Chiba, S., Okamoto, S. ... Sakamaki, H. (2016). Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncology Reports, 36, 2976-2982. https://doi.org/10.3892/or.2016.5110
MLA
Hagihara, M., Iriyama, N., Yoshida, C., Wakita, H., Chiba, S., Okamoto, S., Kawakami, K., Takezako, N., Kumagai, T., Inokuchi, K., Ohyashiki, K., Taguchi, J., Yano, S., Igarashi, T., Kouzai, Y., Morita, S., Sakamoto, J., Sakamaki, H."Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study". Oncology Reports 36.5 (2016): 2976-2982.
Chicago
Hagihara, M., Iriyama, N., Yoshida, C., Wakita, H., Chiba, S., Okamoto, S., Kawakami, K., Takezako, N., Kumagai, T., Inokuchi, K., Ohyashiki, K., Taguchi, J., Yano, S., Igarashi, T., Kouzai, Y., Morita, S., Sakamoto, J., Sakamaki, H."Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study". Oncology Reports 36, no. 5 (2016): 2976-2982. https://doi.org/10.3892/or.2016.5110